Articles tagged with Cancer Patients
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
Moffitt researchers found that cancer patients who believed in vaccine effectiveness and safety were more likely to accept COVID-19 vaccination. High accepters were also more socioeconomically disadvantaged and lived with others, highlighting the need for targeted interventions.
A long-term study of over 300 breast cancer survivors found a link between chronic inflammation and cognitive problems. Higher levels of CRP were related to lower reported cognitive function, suggesting that this common test for inflammation may also indicate risk for cognitive concerns.
A recent study published in Acta Oncologica found that young women who have had cancer are at a higher risk of experiencing sexual problems, including loss of libido and intimacy issues. The study, which surveyed nearly 700 women, suggests that the type and intensity of cancer treatment can influence a patient's sex life.
A recent study found that cancer biomarker data is biased towards European populations, potentially misclassifying patients of Asian or African descent. The researchers propose a computational approach to correct this bias, which could have significant implications for treatment selection.
Scientists have identified a protein that regulates cancer cell spread and normal tissue cell shedding, potentially leading to new treatments. The research suggests that metastasis is not an abnormal process limited to cancer but a normal process used by healthy cells.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Researchers identified a specific gut bacterium responsible for antibiotic-induced GVHD after stem cell transplants. A sugar supplement was found to improve gut health by distracting the bacteria from attacking mucin in the intestinal lining, reducing complications such as GVHD.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
A USC-led team has found indications for an early breast cancer detection method using high-definition liquid biopsies. The test detected multiple cancer biomarkers, including 'oncosomes,' in the blood samples of most early-stage breast cancer patients.
A new predictive biomarker, RNF43 mutations, has been identified as a significant predictor of response to anti-BRAF/EGFR combinatory therapy in patients with microsatellite stable BRAF V600E metastatic colorectal cancer. This biomarker is associated with improved progression-free and overall survival rates.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
The Leducq Foundation has awarded $7.5 million to UVA researchers, led by Mete Civelek, to investigate sex differences in atherosclerosis and $8 million to Coleen McNamara to advance immunotherapy for cardiovascular disease. These projects aim to improve understanding of heart disease and develop new treatments.
The TTUHSC team will provide no-cost colorectal cancer screening and colonoscopies to underinsured and uninsured people living in South Plains region counties. The FIT-STOP program aims to find signs of early-stage colorectal cancer to prevent treatment needs, leveraging existing relationships with partners.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
UCF researchers have designed a cerium oxide nanoparticle to protect bones against radiation damage from cancer therapy. The treatment also improves bone regeneration and kills cancer cells, reducing the risk of bone fractures and tissue damage.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
A recent study supports fourth vaccination for cancer patients to protect them against COVID-19. Patients with solid tumours and hematological cancers showed a significant increase in antibody levels after a fourth dose of one of the currently approved vaccines.
Researchers at UVA Health System have made a groundbreaking discovery that could boost platelet production on demand to alleviate blood shortages. The finding offers hope for patients with thrombocytopenia and those receiving cord-blood transplants.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Research from UVA Cancer Center finds that an unhealthy gut microbiome can trigger changes in normal breast tissue, facilitating cancer's spread to other parts of the body. The study suggests that targeting the gut-mast cell relationship could help prevent breast cancer recurrence and metastasis.
Researchers found that using the Bazett formula to assess heartbeat rhythms can lead to inaccurate chemotherapy modifications, potentially affecting patient care. Standardizing formulas with electrocardiograms can reduce this risk and improve treatment outcomes.
A recent study led by Drexel University's College of Nursing and Health Professions highlights the importance of nutrition and physical activity for both cancer patients and their caregivers. The research found similarities in beliefs about physical activity and barriers faced by both groups, including fatigue and time constraints.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
The new SIO-ASCO guideline recommends the use of acupuncture, massage therapy, and other integrative therapies for managing breast cancer-related joint pain, general cancer pain, and chemotherapy-induced peripheral neuropathy. The guidelines also acknowledge areas that need further research to support their recommendations.
Researchers found associations between financial hardship, food insecurity, housing instability, and transportation difficulties with increased mortality risk among adults with new cancer diagnosis. The study highlights the importance of addressing social determinants of health for improving patient outcomes.
Researchers found that 12% of cancer survivors lived in poverty, experiencing negative effects on physical and mental health. Financial burden of cancer care persists years after diagnosis, leading to poor health outcomes and increased mortality.
A UC San Diego study found that cancer patients experiencing housing instability had a significantly increased risk of mortality. The research suggests that integrating health and social care can improve patient outcomes by identifying and addressing underlying social risk factors.
A new study urges regulators to take a closer look at the health and safety risks of the growing medicinal and recreational cannabis market. The research team found that many pesticides in cannabis cultivation were highly unlikely to be used, but still detected, highlighting the need for stricter regulations.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
A new combination immunotherapy regimen shows remarkable activity in metastatic colorectal cancer patients without liver metastases, achieving a response rate of 40% and median overall survival exceeding 20 months. The study's findings confirm the importance of the tumor microenvironment in shaping the response to immunotherapy.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
A new study suggests that neoadjuvant novel hormonal therapy followed by prostatectomy can reduce the risk of recurrent and progressive cancer in high-risk prostate cancer patients. After treatment with NHAs, patients were more likely to have negative margins after surgery and fewer cases of biochemical recurrence.
A new blood test has shown promising results for detecting multiple types of cancer from tumor DNA in the blood, enabling early detection and potentially changing cancer screening practices. The test's accuracy and effectiveness have been demonstrated in a recent study, with high sensitivity and specificity rates.
The DeFi trial shows targeting the Notch pathway with nirogacestat improves progression-free survival and reduces symptoms in patients with desmoid tumours. Patients reported a statistically significant benefit in reduced pain, symptom burden, and improved quality of life.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
Researchers have developed a new safety system for CAR-T cells, called VIPER CAR-T cells, that can be turned on or off. This allows doctors to target cancer more aggressively while minimizing side effects. The new system uses an FDA-approved antiviral drug to control the cell's activity.
Late-breaking results at ESMO Congress 2022 reveal a strong association between air pollution and non-small cell lung cancer, with exposure to particulate matter linked to increased risk. The research underscores the need for environmental sustainability in oncology, particularly in cancer prevention and early detection.
A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
The PROSPER RCC trial showed no difference in recurrence-free survival between arms, with higher adverse events reported in the nivolumab arm. The trial's results inform future research on neoadjuvant trials in high-risk renal cell carcinoma.
A study from the University of Gothenburg found that the number of surgeries performed by a urology surgeon has no effect on men's risk of developing postoperative urinary incontinence after prostate cancer surgery. The researchers analyzed data from over 4,600 men who underwent robot-assisted radical prostatectomy between 2017 and 2019.
Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...
Breast cancer recurrence and metastatic spread remain a significant challenge, with researchers identifying a metabolic signature that can predict patient outcomes. The signature could be used to develop new therapies targeting cancer metabolism.
A large study found that obstructive sleep apnea is independently associated with an increased risk of cancer. Patients with more severe OSA were also at a greater risk of developing blood clots. Additionally, a second study linked OSA to a decline in mental processing powers, particularly in the elderly.
A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
Researchers identified five new hepatoblastoma tumor signatures that could help predict responses to chemotherapy treatments. The study used single-cell transcriptomic techniques to analyze tumors from infants and children, providing a window into normal development and cancer.
A study from Lund University found that Caveolin-1 protein levels in surrounding tumour tissue affect breast cancer prognosis. The study suggests that this protein could be used as a marker for precise prognosis and treatment choice.
Researchers at UVA have discovered the mechanism behind gene regulation during organ development, shedding light on how genetic material interacts with transcription factors to create different cell types. The study's findings could offer insights into the initiation of certain cancers and inspire new therapeutic development.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Researchers have successfully prevented neuropathic pain associated with chemotherapy in mice treated with oxaliplatin. A Sigma-1 receptor antagonist prevents the development of neuropathy by modulating the TRPA1 ion channel, offering hope for a new therapy to treat debilitating side effects.
Researchers have discovered that reduced TGFBR2 abundance is significantly associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. An AI-based process accurately identified HCC tissue, confirming the biomarker's potential for early detection.
Cancer patients in rural areas experience higher mortality rates and are more likely to miss radiation appointments, leading to poorer overall survival. The study suggests that targeted support programs like patient navigation can help reduce disparities in cancer care.
A new study by Dana-Farber Cancer Institute found that dispensaries often prioritize sales skills over cannabis therapeutics training, leading to a lack of reliable guidance for patients. The study's findings highlight the need for standardized training and education in cannabis therapy to ensure patients receive accurate information.
Research suggests that cancer-related fatigue (CRF) contributes to balance problems in breast cancer survivors, even after chemotherapy. CRF predicts greater postural sway and changes in 'sit-to-stand' function, highlighting the need for rehabilitation professionals to consider CRF in exercise prescriptions.
A study published in Patterns shows that five digital medicine companies share browsing data related to health topics with Facebook for lead generation and advertising purposes. The researchers found that two companies targeted ads consistent with their own privacy policies, while the other three did not comply with their policies.